Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of FXS6837 versus eculizumab in complement inhibitor-naive PNH
CTR20263673Phase 3Active
- Sponsor
- Xinghao Pengbo
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of FXS6837 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Xinghao Pengbo. Started Sep 2026; status: active.
02
Drugs
FXS6837
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20263673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263673.